
## **SUMMARY OF SELECTED REPORTABLE DISEASES**

## January-December, 2024

Case counts refer to confirmed and probable cases.



Comparison of YTD Count to 5-year median

**ABOVE YTD** 

**BELOW YTD** 



## **SUMMARY OF SELECTED REPORTABLE DISEASES Jan-December, 2024**

Case counts refer to confirmed and probable cases  $^{1, 2, 3}$ 

	Jan-December 2024	Jan-December 2023	5-year Median Jan-December
VACCINE PREVENTABLE DISEASES:			
Haemophilus influenzae, serotype b invasive disease, all ages	1	0	1
Haemophilus influenzae, serotype b, invasive disease, <5 years of age	1	0	1
Influenza <sup>4</sup>	25,257	23,954	8,262
Measles	5	0	0
Meningococcal infection, invasive	14	8	3
Mumps	2	6	6
Pertussis, probable and confirmed	787	344	331
Pertussis, confirmed cases only	431	176	176
ENTERIC DISEASES:			
Amebiasis	22	13	13
Campylobacteriosis	1,483	1,361	1,508
Cryptosporidiosis	146	129	127
E.coli, Shiga toxin-producing	358	329	297
Giardiasis	192	160	113
Listeriosis	7	9	9
Salmonellosis	1,163	1,242	954
Shigellosis	553	516	426
Vibrio infection	69	61	52
VIRAL HEPATITIDES:	1		1
Hepatitis A	38	61	59
Hepatitis B, acute	42	37	37
Hepatitis B, non-acute	1,002	1,208	1,153
INVASIVE DISEASES:	7	, , ,	,
Legionellosis	150	115	112
Streptococcus pneumoniae	1152	1133	798
Streptococcus group A	1319	1337	966
Streptococcus group B in infants <90 days of age	29	32	34
Methicillin-resistant Staphylococcus aureus	1,566	1,539	1,498
VECTOR-BORNE & ZOONOTIC DISEASES:	1,500	1,557	1,770
Chikungunya	3	0	0
Dengue	52	31	18
Hantavirus infection	11	6	10
Malaria	34	51	26
Rocky Mountain spotted fever	7	48	38
West Nile virus infection	31	82	82
Zika	0	0	0
SEXUALLY TRANSMITTED INFECTIONS:	U	U	U
Chlamydia	26.460	41.072	40.010
Gonorrhea	36,469	41,073	40,818
	12,542	14,181	16,180
Syphilis, primary and secondary	1,006	1,794	1,794
Syphilis, early non-primary non-secondary	1,087	1,827	1,475
Syphilis, unknown duration or late	2,566	4,108	2,691
Syphilis, congenital <sup>5</sup>	165	233	183
MYCOSIS:	15.004	40.000	10.000
Coccidioidomycosis	15,024	10,990	10,990
CARBAPENEM-RESISTANT ENTEROBACTERALES AND CARBAPENEMASE PRODUCING		1.020	502
Carbapenem-Resistant Enterobacterales (CRE)	1,579	1,028	503
CRE Klebsiella pneumoniae carbapenemase (KPC) <sup>6</sup>	137	95	95
CRE New Delhi Metallo-beta-lactamase (NDM) <sup>6</sup>	1,134	686	167
CRE Verona Integron-Mediated Metallo-ß-lactamase (VIM) <sup>6</sup>	31	16	10
CRE Oxacillinase-48-type carbapenemases (OXA-48) <sup>6</sup>	9	7	5
CRE Imipenemase Metallo-\(\beta\)-lactamase (IMP)\(^6\)	0	1	1

<sup>&</sup>lt;sup>1</sup> Data are provisional and reflect case reports to Arizona Department of Health Services during this period.

Animal rabies stats can be found at https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/rabies/data/2024.pdf.

 $<sup>^{2}</sup>$  These counts reflect the year reported or tested and not the date infected.

<sup>&</sup>lt;sup>3</sup> During 2024, the 5-year median includes cases reported 2019 through 2023.

 $<sup>^4</sup>$  Influenza is lab-confirmed only and represents "season-to-date" cases (counting from the previous September) rather than year-to-date.

<sup>&</sup>lt;sup>5</sup> Congenital syphilis cases are counted in their year of birth; counts may vary as additional cases can be reported at any time.

 $<sup>^{6}</sup>$  Note that cases can have multiple mechanisms identified and therefore will be counted in multiple mechanism categories.